ASX ANNOUNCEMENT

ViraDx™ Receives Interim Order Authorisation in Canada

- *Lumos to launch ViraDx™ in Canada following Interim Order authorisation from Health Canada.*
- *ViraDx is a three-in-one COVID-19/Flu A/Flu B test for use by healthcare professionals.*
- *ViraDx will be marketed through distributor sales channels already established in Canada for CoviDx™ and FebriDx®.*
- *ViraDx is under review with the U.S. FDA.*

MELBOURNE, Australia (27 June 2022): Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, has received Interim Order authorization from Health Canada for its ViraDx three-in-one rapid antigen test for COVID-19/Flu A/Flu B in Canada.

Subject to demand in Canada, Lumos is ready to commence production and shipping of ViraDx for use by healthcare professionals in Canada where it will be distributed by the Company's established Canadian distribution partners. ViraDx is currently under review by the U.S. FDA for Emergency Use Authorisation (EUA). If successful, Lumos intends to expand its North American sales and marketing efforts to include U.S. healthcare providers in hospitals and outpatient care settings that serve patients with acute respiratory infections.

"With a single sample, ViraDx provides three simultaneous test results—giving clinicians in outpatient care settings the ability to differentiate these viruses and providing a higher level of confidence as they consider time-sensitive antiviral treatment options," said Doug Ward CEO of Lumos Diagnostics. "At this stage, the potential demand for ViraDx in Canada is uncertain due to the evolving public health response to COVID-19 and limited reimbursement coverage for POC 'flu testing. However, this Interim Order authorization from Health Canada does provide clear validation of the quality of our clinical and regulatory data for ViraDx and an opportunity to co-market it alongside FebriDx®. Lumos has an EUA application for

ViraDx that is currently under review by the U. S. FDA and is expecting an outcome from that review process in the coming months."

This announcement has been approved by the Lumos Disclosure Committee

About ViraDx

The 15-minute ViraDx COVID-19/Flu A/Flu B rapid antigen test uses an anterior nasal or nasopharyngeal swab sample to simultaneously detect and differentiate SARS-CoV-2, influenza A and influenza B—quickly giving healthcare providers results. ViraDx is packaged as a test kit with individually packaged reagents to allow for increased test distribution. The qualitative results are visually read, easy to interpret, and require no additional instruments, equipment or special storage, which makes the ViraDx test a practical solution for virtually any healthcare setting.

ViraDx is manufactured in the U.S. and made available to healthcare professionals exclusively through Lumos Diagnostics and its Canadian distributors.

# # #

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Australia Media Contact:

Matt Wright
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Relations Contact:
Matthijs Smith
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598